We thank D'Amato et al. (1) and Zeldis et al. (2) for their interest and comments on our article in PNAS (3). We carried out a screen of lenalidomide and pomalidomide primarily in chicken and zebrafish embryos, but also in several in vitro assays. Our goal was to determine any differential actions or responses and to visualize effects live and in vivo (3). Identifying such differences, we reasoned, could help understand the underlying or differential mechanisms of actions of each of these compounds. In addition, this screen provides proof-of-principle to potentially use the chicken and zebrafish embryos to initially screen modified analogs of the compounds to identify those with cell/tissue-specific actions and identify potential adverse reactions (3, 4) . This initial screen would require validation in higher species/ clinical trials.
We mentioned in our article (3) that species-specific differences have been reported for pomalidomide in higher species. That pomalidomide exhibits species-specific differences, like thalidomide, is of interest in itself and understanding this mechanism should help further understand the mechanisms of actions of these drugs. Our data also indicate that pomalidomide does behave differently to thalidomide and lenalidomide.
We found that pomalidomide at antiinflammatory concentrations did not affect angiogenesis in in vivo or in vitro human umbilical vein endothelial cells (HUVEC) cell assays (3). This finding is consistent with that of previous work by Lentzsch, D'Amato and colleagues (5) indicating pomalidomide had no direct effect upon proliferation of HUVEC cells in vitro, even at high concentrations up to 100 μM (5). We also did not find any cytoskeletal changes in HUVEC cells following pomalidomide exposure (3). Our work indicates that pomalidomide affects inflammatory response cells primarily, which was also shown by another study (4). The fact that pomalidomide inhibits VEGF-stimulated (5, 6) but not non-VEGF-stimulated angiogenesis (3) further points to the drug's selectivity and target specificity that may also be species-dependent.
The concentrations we used throughout were determined by establishing the maximal anti-inflammatory response (via in vivo assays and in vitro assays to determine TNF-α levels) (3). The concentrations tested in the embryos and in vitro are within ranges used by other in vivo and in vitro studies, including those mentioned in our report (3, 5) . It is not known what the C max of these compounds is in chicken and zebrafish embryos. Given the way the drug is applied, globally into chick eggs or into the water containing zebrafish embryos, exactly how much actually enters the embryo is unclear. However, we observed different responses to each compound tested but never saw teratogenesis or changed angiogenesis with pomalidomide.
We agree that basing conclusions about clinical human effects from animal studies should be done with extreme caution. Indeed, many mammalian models used to study and induce teratogenesis use high concentrations of thalidomide and its analogs-for example, 150 mg/kg in rabbits (7), 50 mg/kg in mice (5)-underlining that translation from different animal species to humans is always difficult and further testing is always required to check actions in humans. However, these animal assays do shed light on actions of the drug and its potential side-effects or benefits. In addition, our research underscores the importance of understanding a drug's targets and species specificity to improve its efficacy and safety in developing future analogs.
It was not our intention to imply or otherwise suggest that our data indicate that pomalidomide is safe for pregnant women. We would never condone such application nor do we condone use of any drugs of this class during pregnancy without full assessment and appropriate regulatory approval. We agree that further testing for potential use in other clinical conditions is always required in higher species and through clinical trials. In addition we agree that monitoring of pomalidomide use in patients through the Risk Evaluation and Management System is a necessity, as is the monitoring of patients for symptoms of peripheral neuropathy. We apologize for not making this point clearer in the article and for any unintended confusion. We further apologize to the many authors we were unable to cite because of space constraints, including the prior works of D'Amato and colleagues (1, 5 
